Special Considerations for Advanced Heart Failure Surgeries: Durable Left Ventricular Devices and Heart Transplantation.
Armaan Fazal AkbarAlice L ZhouAnnie WangAmy S N FengAlexandra A RizaldiJessica M RuckAhmet KılıçPublished in: Journal of cardiovascular development and disease (2024)
Heart transplantation and durable left ventricular assist devices (LVADs) represent two definitive therapies for end-stage heart failure in the modern era. Despite technological advances, both treatment modalities continue to experience unique risks that impact surgical and perioperative decision-making. Here, we review special populations and factors that impact risk in LVAD and heart transplant surgery and examine critical decisions in the management of these patients. As both heart transplantation and the use of durable LVADs as destination therapy continue to increase, these considerations will be of increasing relevance in managing advanced heart failure and improving outcomes.
Keyphrases
- heart failure
- left ventricular
- cardiac resynchronization therapy
- decision making
- end stage renal disease
- ejection fraction
- acute heart failure
- minimally invasive
- acute myocardial infarction
- chronic kidney disease
- hypertrophic cardiomyopathy
- atrial fibrillation
- aortic stenosis
- patients undergoing
- prognostic factors
- mitral valve
- cardiac surgery
- coronary artery bypass
- human health
- coronary artery disease
- stem cells
- acute kidney injury
- mesenchymal stem cells
- bone marrow
- risk assessment
- combination therapy
- weight loss
- patient reported
- percutaneous coronary intervention
- smoking cessation